Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2631
Título : A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
Autor : García-Gutiérrez, Valentín
Gómez-Casares, María T
Puerta, José M
Alonso-Domínguez, Juan M
Osorio, Santiago
Hernández-Boluda, Juan C
Collado, Rosa
Ramírez, María J
Ibáñez, Fátima
Martín, María L
Rodríguez-Gambarte, Juan D
Martínez-Laperche, Carolina
Gómez, Montse
Fiallo, Dolly V
Redondo, Sara
Rodríguez, Alicia
Ruiz-Nuño, Concepción
Steegmann, Juan L
Jiménez-Velasco, Antonio
Filiación: [García-Gutiérrez,V; Rodríguez-Gambarte,JD] Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Gómez-Casares,MT; Fiallo,DV] Hematology Department, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain. [Puerta,JM] Unidad de Gestión Clínica Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Alonso-Domínguez,JM] Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. [Osorio,S; Martínez-Laperche,C; Redondo,S] Hematology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain. [Hernández-Boluda,JC; Gómez,M] Hematology Department, Hospital Clínico, Valencia, Spain. [Collado,R] Genetic Laboratory, Hematology Department, Consorcio Hospital General Universitario, Valencia, Spain. [Ramírez,MJ] Hematology Department, Hospital de Jerez de la Frontera, Cádiz, Spain. [Ibáñez,F] Hematology Department, Hospital San Pedro de Alcántara, Cáceres, Spain. [Martín,ML; Rodríguez,A] Hematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Ruiz-Nuño,C; Jiménez-Velasco,A] Hematology Department, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain. [Steegmann,JL] Hematology Department & IIS-IP, Hospital Universitario de la Princesa, Madrid, Spain.
Grupo de Investigación: Spanish Group of Chronic Myeloid Leukemia (GELMC)
Palabras clave : Humanos
Leucemia mielógena crónica BCR-ABL positiva
Leucemia mieloide de fase crónica
Reacción en cadena de la polimerasa
Probabilidad
Estándares de referencia
MeSH: Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive::Leukemia, Myeloid, Chronic-Phase
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Nucleic Acid Amplification Techniques::Polymerase Chain Reaction
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Weights and Measures::Reference Standards
Fecha de publicación : 9-Mar-2017
Editorial : Public Library of Science
Cita Bibliográfica: García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. PLoS One. 2017 Mar 9;12(3):e0173532.
Abstract: In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlated with further outcomes. Monitoring molecular responses in CML using the GeneXpert (Cepheid) platform has shown an optimal correlation with standardized RQ-PCR (IS) when measuring BCR-ABL1 levels lower than 10%, as it is not accurate for values over 10%. The aim of the present study was to determine the predictive molecular value at three months on different outcome variables using the Xpert BCR-ABL1 MonitorTM assay (Xpert BCR-ABL1). We monitored 125 newly diagnosed consecutive CML patients in the chronic phase (CML-CP) using an automated method: Xpert BCR-ABL1. Only 5% of patients did not achieve an optimal response at 3 months, and the 10% BCR-ABL1 cutoff defined by RQ-PCR (IS) methods was unable to identify significant differences in the probabilities of achieving a complete cytogenetic response (CCyR) (50% vs. 87%, p = 0.1) or a major molecular response (MMR) (60% vs. 80%, p = 0.29) by 12 months. In contrast, a cutoff of 1.5% more accurately identified differences in the probabilities of achieving CCyR (98% vs. 54%, p<0.001) and MMR (88% vs. 56%, p<0.001) by 12 months, as well as probabilities of treatment changes (p = 0.005). Therefore, when using the Xpert BCR-ABL1 assay, a cutoff of 1.5% at 3 months could with high probability identify patients able to achieve an optimal response at 12 months.
Descripción : Members of the Spanish Group of Chronic Myeloid Leukemia (GELMC) are: Valentín García-Gutiérrez (Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain). María T. Gómez-Casares (Hematology Department, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain). José M. Puerta (Unidad de Gestión Clínica Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain). Juan M. Alonso-Domínguez (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain). Santiago Osorio (Hematology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain). Juan C. Hernández-Boluda (Hematology Department, Hospital Clínico, Valencia, Spain). Rosa Collado (Genetic Laboratory, Hematology Department, Consorcio Hospital General Universitario, Valencia, Spain). María J. Ramírez (Hematology Department, Hospital de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain). Fátima Ibáñez (Hematology Department, Hospital San Pedro de Alcántara, Cáceres, Spain). Alicia Rodríguez (Hematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain). Concepción Ruiz-Nuño and Antonio Jiménez-Velasco (Hematology Department, Hospital Regional Universitario de Málaga, IBIMA, Spain). Juan L. Steegmann (Hematology Department & IIS-IP. Hospital Universitario de la Princesa, Madrid, Spain.
URI: http://hdl.handle.net/10668/2631
Versión del editor : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173532#abstract0
DOI: 10.1371/journal.pone.0173532
ISSN : 1932-6203 (Online)
Appears in Collections:01- Artículos - IBIMA. Instituto de Investigación Biomédica de Málaga
01- Artículos - Hospital Regional de Málaga
01- Artículos - Hospital Virgen Macarena
01- Artículos - Hospital de Jerez
01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
GarciaGutierrez_ABCR-ABL1.pdfArtículo publicado767,75 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons